Agilent Expands Portfolio of Probes for In Situ Hybridization

Better signal-to-noise ratio makes data easier to interpret

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent
Technologies Inc.
(NYSE: A) today announced the release of a range
of new probes for in situ hybridization, a technique used in
pathology laboratories to obtain information about gene expression.

The new probes address the need to cleanly and accurately interpret data
from both fluorescence in situ hybridization (FISH) and
chromogenic in situ hybridization (CISH).

The new Agilent SureFISH probes include Break-Apart: MALT1, BCL2, BCL6,
CCND1, MYC, IGH, Dual Fusion: IGH/CCND1, IGH/MYC, and IGH/BCL2.

The new CISH probes include (ASR) EBER RNA CISH and Kappa and Lambda
mRNA CISH probes.

“Our CISH and SureFISH probes are manufactured with Agilent’s unique
process, which uses synthetic oligonucleotides rather than the more
common bacterial artificial chromosomes,” said Kamni Vijay, Agilent vice
president and general manager of the company’s genomics division. “This
innovative approach ensures high signal-to-noise ratios with a low
background signal, making the interpretation of the data faster, easier,
and more accurate.”

Vijay noted that Agilent’s new probes will bring the precision of
oligonucleotide-based in situ hybridization into more
laboratories.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences,
diagnostics, and applied chemical markets. With more than 50 years of
insight and innovation, Agilent instruments, software, services,
solutions, and people provide trusted answers to customers’ most
challenging questions. The company generated revenues of $4.47 billion
in fiscal 2017 and employs 14,200 people worldwide. Information about
Agilent is available at www.agilent.com.

Contacts

Agilent Technologies
Victoria Wadsworth-Hansen, +1-408-553-2005
+45
2933 6980
victoria.wadsworth-hansen@agilent.com